Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Shares Jump 19 Percent on Strong Q1 Revenue Growth

NEW YORK, May 4 (GenomeWeb News) - Shares in Nanogen were up 19.10 percent, or $.51, at $3.18 in mid-afternoon trading after the company reported a 45-percent jump in first-quarter revenue.


Posting its first quarter financials yesterday afternoon, Nanogen said total revenues increased to $3.2 million from $2.2 million year over year. Driving this growth was a surge in licensing fees, which grew to $1.7 million from $152,000 year over year.


It was the first quarter to include revenues from Epoch Biosciences, which Nanogen acquired in December 2004. Receipts from product sales, sponsored research, and contracts and grants all fell in the first quarter.


Nanogen said R&D spending for the three months ended March 31 increased to $4.9 million from $4.3 million in the year-ago period.


Net loss for the quarter jumped to $8.3 million, or $.17 per basic share, from $5.4 million, or $.20 per share, year over year.


Nanogen said it had around $12.7 million in cash and equivalents and $27.1 million in short-term investments as of March 31.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.